NFKB1 and gastric cancer: Indeed, in a mice GC model, intraperitoneal administration of RelA siRNA or nafamostat mesilate (FUT-175), an inhibitor of serine proteases and NF-κB, potentiated Paclitaxel effects leading to a reduction of peritoneal metastasis and increasing survival [157,158].